======= KDM3B ======= == Gene Information == * **Official Symbol**: KDM3B * **Official Name**: lysine demethylase 3B * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=51780|51780]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q7LBC6|Q7LBC6]] * **Interactions**: [[https://thebiogrid.org/search.php?search=KDM3B&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KDM3B|Open PubMed]] * **OMIM**: [[https://omim.org/entry/609373|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Histone demethylase that specifically demethylates 'Lys- 9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May have tumor suppressor activity. {ECO:0000269|PubMed:16603237}. |JmjC| |response to cisplatin| |histone demethylase activity (H3-K9 specific)| |histone H3-K9 demethylation| |antioxidant activity| |dioxygenase activity| |histone lysine demethylation| |histone demethylation| |protein demethylation| |protein dealkylation| |demethylation| |chromatin DNA binding| |transcription regulatory region sequence-specific DNA binding| |cellular oxidant detoxification| |response to antineoplastic agent| |cellular detoxification| |chromatin| |detoxification| |cellular response to toxic substance| |histone modification| |covalent chromatin modification| |response to toxic substance| |chromatin organization| |oxidation-reduction process| |response to drug| |chromosome organization| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp215|Colchicine 0.009μM R05 exp215]]|-2.1| |[[:results:exp245|UM0011500 5μM R05 exp245]]|-1.73| |[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|1.72| |[[:results:exp443|SNS-032 15μM R08 exp443]]|1.73| |[[:results:exp453|B02 10μM R08 exp453]]|1.78| |[[:results:exp93|DABN racemic mixture R03 exp93]]|1.8| |[[:results:exp239|PFI-2 4μM R05 exp239]]|1.8| |[[:results:exp341|BRD2 inhibitor II 20μM R07 exp341]]|1.81| |[[:results:exp419|Tunicamycin 0.04 to 0.075μM on day4 R07 exp419]]|1.83| |[[:results:exp234|Ethanol 0.01 R05 exp234]]|1.91| |[[:results:exp525|Sulforaphane 9μM R08 exp525]]|1.91| |[[:results:exp451|Atovaquone 15μM R08 exp451]]|1.96| |[[:results:exp499|LY2090314 0.003μM R08 exp499]]|1.96| |[[:results:exp116|AICAR 240μM R03 exp116]]|1.99| |[[:results:exp416|Tubacin 1.6μM R07 exp416]]|2.04| |[[:results:exp274|Citral 50μM R06 exp274]]|2.06| |[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|2.06| |[[:results:exp510|Nicotine 3000μM R08 exp510]]|2.06| |[[:results:exp326|CCT251545 20μM R07 exp326]]|2.13| |[[:results:exp497|Lead acetate 2000μM R08 exp497]]|2.16| |[[:results:exp134|MS023 2μM R03 exp134]]|2.21| |[[:results:exp531|THZ1 0.06μM R08 exp531]]|2.33| |[[:results:exp502|Milciclib 2μM R08 exp502]]|2.34| |[[:results:exp84|UM0125461 0.74μM R02 exp84]]|2.43| |[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|2.56| |[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|2.67| |[[:results:exp439|QNZ 0.01μM R08 exp439]]|2.76| |[[:results:exp115|A-366 10μM R03 exp115]]|2.93| |[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|2.95| ^Gene^Correlation^ |[[:human genes:m:mapkap1|MAPKAP1]]|0.419| |[[:human genes:u:urm1|URM1]]|0.402| Global Fraction of Cell Lines Where Essential: 0/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 15931 * **Expression level (log2 read counts)**: 7.82 {{:chemogenomics:nalm6 dist.png?nolink |}}